Beta
170555

Relation of Estrogen Receptor Expression to Recurrence and Survival in Early and Locally Advanced Breast Cancer

Article

Last updated: 22 Jan 2023

Subjects

-

Tags

-

Abstract

Background: Breast cancer is the most diagnosed cancer among women worldwide, accounting for almost 1 in 4 cancer cases. It is the second most frequent and the leading cause of death from cancer in women. In breast cancer, assessment of hormonal receptor status is fundamental having both prognostic and predictive role. The studies that focused on the impact of estrogen receptor (ER) expression showed controversial results. So in this study our aim was to determine the effect of ER expression on disease recurrence and survival in non-metastatic breast cancer patients.
Patients and methods : This is a retrospective study including 110 non metastatic breast cancer patients with the exclusion of human epidermal growth factor receptor 2 (Her2) positive cases starting from January 2006 to December 2010. Patients were divided into three groups hormonal negative (0%), low/ intermediate (1-50%) and strong (51-100%) ER expression according to the quantitative ER measurement.
Results: There was a positive correlation between the level of ER expression and overall survival (OS) which was not true for disease free survival (DFS).
Conclusion: The relation between the level of ER expression and survival was significant while there was no significant relation to disease recurrence.

DOI

10.21608/secioj.2021.170555

Keywords

estrogen receptor, breast cancer, Survival, Recurrence

Volume

9

Article Issue

2

Related Issue

24246

Issue Date

2021-04-01

Receive Date

2021-04-18

Publish Date

2021-04-30

Page Start

112

Page End

117

Print ISSN

2537-0995

Online ISSN

2314-8500

Link

https://secioj.journals.ekb.eg/article_170555.html

Detail API

https://secioj.journals.ekb.eg/service?article_code=170555

Order

9

Publication Type

Journal

Publication Title

SECI Oncology Journal

Publication Link

https://secioj.journals.ekb.eg/

MainTitle

-

Details

Type

Article

Created At

22 Jan 2023